Mineralys Therapeutics terminates ATM prospectus supplement, halts sales until new filing

Mineralys Therapeutics, Inc.

Delivered written notice to BofA Securities and Evercore terminating prospectus supplement dated April 11, 2024.
No further sales of common stock under the Sales Agreement will occur until a new prospectus supplement is filed.
The underlying ATM Equity Offering Sales Agreement (March 21, 2024) remains in full force and effect.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.